泌尿系统癌症的液体活检检查：重点是尿液。

IF 2.3 3区医学 Q3 ONCOLOGY

Urologic Oncology-seminars and Original Investigations Pub Date : 2025-08-09 DOI:10.1016/j.urolonc.2025.07.034

Pasquale Pisapia M.D., Ph.D. , Francesco Pepe Ph.D. , Gianluca Russo Ph.D. , Raffaele Capoluongo M.D., Ph.D. , Mariano Coppola M.D., Ph.D. , Francesco Del Giudice M.D., Ph.D. , Matteo Ferro M.D., Ph.D. , Antonio Madonna M.D., Ph.D. , Michele Musone M.D., Ph.D. , Giancarlo Troncone M.D., Ph.D. , Umberto Malapelle Ph.D. , Felice Crocetto M.D., Ph.D.

{"title":"泌尿系统癌症的液体活检检查：重点是尿液。","authors":"Pasquale Pisapia M.D., Ph.D. , Francesco Pepe Ph.D. , Gianluca Russo Ph.D. , Raffaele Capoluongo M.D., Ph.D. , Mariano Coppola M.D., Ph.D. , Francesco Del Giudice M.D., Ph.D. , Matteo Ferro M.D., Ph.D. , Antonio Madonna M.D., Ph.D. , Michele Musone M.D., Ph.D. , Giancarlo Troncone M.D., Ph.D. , Umberto Malapelle Ph.D. , Felice Crocetto M.D., Ph.D.","doi":"10.1016/j.urolonc.2025.07.034","DOIUrl":null,"url":null,"abstract":"<div><div>Liquid biopsy has significantly transformed the management of patients with urological cancers. In particular, alternative sources of tumor nucleic acids and analytes beyond blood have taken on a crucial role in these malignancies. In this context, urine represents a valuable alternative to blood and should be considered within an expanded concept of liquid biopsy. Urine acts as a natural ultracentrifuge of blood, making it a complementary molecular resource alongside plasma. This review aims to summarize the potential applications of urine biomarker analysis in the management of urological malignancies, highlighting current challenges and future perspectives for integrating liquid biopsy into clinical practice.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 10","pages":"Pages 553-564"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liquid biopsy testing in urological cancers: Focus on urine\",\"authors\":\"Pasquale Pisapia M.D., Ph.D. , Francesco Pepe Ph.D. , Gianluca Russo Ph.D. , Raffaele Capoluongo M.D., Ph.D. , Mariano Coppola M.D., Ph.D. , Francesco Del Giudice M.D., Ph.D. , Matteo Ferro M.D., Ph.D. , Antonio Madonna M.D., Ph.D. , Michele Musone M.D., Ph.D. , Giancarlo Troncone M.D., Ph.D. , Umberto Malapelle Ph.D. , Felice Crocetto M.D., Ph.D.\",\"doi\":\"10.1016/j.urolonc.2025.07.034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Liquid biopsy has significantly transformed the management of patients with urological cancers. In particular, alternative sources of tumor nucleic acids and analytes beyond blood have taken on a crucial role in these malignancies. In this context, urine represents a valuable alternative to blood and should be considered within an expanded concept of liquid biopsy. Urine acts as a natural ultracentrifuge of blood, making it a complementary molecular resource alongside plasma. This review aims to summarize the potential applications of urine biomarker analysis in the management of urological malignancies, highlighting current challenges and future perspectives for integrating liquid biopsy into clinical practice.</div></div>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\"43 10\",\"pages\":\"Pages 553-564\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1078143925003047\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1078143925003047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

液体活检极大地改变了泌尿系统癌症患者的治疗。特别是，血液以外的肿瘤核酸和分析物的替代来源在这些恶性肿瘤中起着至关重要的作用。在这种情况下，尿液代表了血液的一种有价值的替代品，应该在扩大的液体活检概念中加以考虑。尿液作为血液的天然超离心机，使其成为血浆的补充分子资源。本文旨在总结尿液生物标志物分析在泌尿系统恶性肿瘤治疗中的潜在应用，强调将液体活检纳入临床实践的当前挑战和未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Liquid biopsy testing in urological cancers: Focus on urine

Liquid biopsy has significantly transformed the management of patients with urological cancers. In particular, alternative sources of tumor nucleic acids and analytes beyond blood have taken on a crucial role in these malignancies. In this context, urine represents a valuable alternative to blood and should be considered within an expanded concept of liquid biopsy. Urine acts as a natural ultracentrifuge of blood, making it a complementary molecular resource alongside plasma. This review aims to summarize the potential applications of urine biomarker analysis in the management of urological malignancies, highlighting current challenges and future perspectives for integrating liquid biopsy into clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Urologic Oncology-seminars and Original Investigations 医学-泌尿学与肾脏学

CiteScore

4.80

自引率

3.70%

发文量

297

审稿时长

7.6 weeks

期刊介绍： Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.